References
- Charles J. Parker. The pathophysiology of paroxysmal nocturnal
hemoglobinuria. Exp Hematol. 2007,5:523-533.
- Kinoshita T. Molecular genetics, biochemistry, and biology of PNH.
Rinsho Ketsueki. 2017;58(4):353-362.
- Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of
the complement inhibitor eculizumab for the treatment of patients with
paroxysmal nocturnal hemoglobinuria[J]. Blood,
2008,111(4):1840-1847.
- .Sicre de Fontbrune F, Peffault de Latour R. Ten years of clinical
experience with eculizumab in patients with paroxysmal nocturnal
hemoglobinuria[J]. Semin Hematol,2018,55(3):124-129.
- Patriquin CJ, Kiss T, Caplan S, et al. How we treat paroxysmal
nocturnal hemoglobinuria: A consensus statement of the Canadian PNH
Network and review of the national registry[J]. Eur J Haematol,
2019,102(1):36-52.
- Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab
(ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients
with PNH: the 302 study[J]. Blood, 2019,133(6):540-549.
- Röth A, Nishimura JI, Nagy Z, et al. The complement C5 inhibitor
crovalimab in paroxysmal nocturnal hemoglobinuria[J]. Blood, 2020,
135 (12): 912-920.
- Schols S, Nunn MA, Mackie I, et al. Successful treatment of a PNH
patient non-responsive to eculizumab with the novel complement C5
inhibitor coversin (nomacopan)[J]. Br J Haematol, 2020,
188(2):334-337.
- .Schatz-Jakobsen JA, Zhang Y, Johnson K, et al. Structural Basis for
Eculizumab-Mediated Inhibition of the Complement Terminal Pathway. J
Immunol. 2016,97(1):337-44.
- Alfinito F, Ruggiero G, Sica M, et al. Eculizumab treatment modified
the immune profile of PNH patients. Immunobiology.
2012,217(7):698-703.
- Cooper JP, Farah RJ, Stevenson PA, Gooley TA, Storb R, Scott BL. Biol
Hematopoietic Cell
Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of
Eculizumab.Blood Marrow Transplant. 2019 Jul;25(7):1331-1339.
- .Lee SE,Park SS, Jeon YW, et al. Outcomes of allogeneic stem cell
transplantation in patients with paroxysmal nocturnal hemoglobinuria
with or without aplastic anemia. Eur J Haematol. 2017 Jul 4.
- Tian H, Liu L, Chen J, Xu Y, Jin Z, Miao M, Fu Z, Qiu H, Sun A, Wu D.
Haploidentical hematopoietic stem cell transplant
in paroxysmal nocturnal hemoglobinuria. Leuk Lymphoma.
2016;57(4):835-41.
- Chen F, Wu D, Tang X, et al. Outcomes of allogeneic hematopoietic stem
cell transplantation for 18 patients with paroxysmal nocturnal
haemoglobinuria. Zhonghua Xue Ye Xue Za Zhi. 2015 Dec;36(12):1005-10.
- Chinese Society of Hematology, Chinese Medical Association. Expert
consensus of diagnosis and treatment of paroxysmal nocturnal
hemoglobinuria. Zhonghua Xue Ye Xue Za Zhi 34:276-279, 2013.
- Ge ML, Li XX, Shao YQ, Shi J, Zheng YZ. Clinical Analysis of 70 Adult
Patients with Paroxysmal Nocturnal Hemoglobinuria. Journal of
Experimental Hematology. 2015, 23(3): 774~778.
- Fu R, Li L, Li L, Liu H, Zhang T, Ding S, Wang G, Song J, Wang H, Xing
L, Guan J, Shao Z.
Analysis of clinical
characteristics of 92 patients with paroxysmal nocturnal
hemoglobinuria: A single institution experience in China. J Clin Lab
Anal. 2020 Jan;34(1):e23008.
- .Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal
haemoglobinuriaNat Rev Dis Primers. 2017 May 18;3:17028.
- N E Hansen, S A Killmann. Paroxysmal nocturnal haemoglobinuria. A
clinical study. Acta Med Scand1968 Dec;184(6):525-41.
- N E Hansen, S A Killmann. Paroxysmal nocturnal haemoglobinuria. A
clinical study. Acta Med Scand1968 Dec;184(6):525-41.
- Xi-feng Dong, Rong Fu, Hua-quan Wang, Zong-hong Shao. Chemotherapy
plus hematopoietic growth factors for refractory paroxysmal nocturnal
hemoglobinuria: diminishing PNH clone and stimulating hematopoisis.
Journal of Society for development in new net environment in
B&H,2012:6,2749-2756.
- Cao YR, Shao ZH, Jia HR, Sun J, Liu H, Wu YH, Qin TJ, Shi J, Bai J, He
GS, Fu R, Zhao MF, Tu HF, Cui ZZ, Yang TY.
Preliminary study of
DA or HA regimen chemotherapy for the treatment of refractory and
relapsed paroxysmal nocturnal hemoglobinuria. Zhonghua Xue Ye Xue Za
Zhi. 2004 Apr;25(4):202-4.
- Shao ZH, Zhao MF, Li K, Liu H, Yang TY, Shi J, He GS, He H, Zhang
H,Chen GB, Chu YL,Yang TY. Efficacy of low-dose combined chemotherapy
on refractory and recurrent paroxysmal nocturnal hemoglobinuria
Chinese Journal of Practical Internal Medicine,2000,20:10,607-609.
- Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the
treatment of paroxysmal nocturnal hemoglobinuria[J]. Ther Adv
Hematol, 2019, 10: 20406207 19874728.
- Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab
(ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients
with PNH: the 302 study[J]. Blood, 2019,133(6):540-549.
- Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, et al. Ravulizumab
(ALXN1210) vs eculizumab in adult patients with PNH naive to
complement inhibitors: the 301 study[J]. Blood, 2019, 133(6):
530-539.
- Risitano AM, Marotta S, Ricci P, et al. Anti-complement treatment for
paroxysmal nocturnal hemoglobinuria: time for proximal complement
inhibition? A position paper from the SAAWP of the EBMT[J]. Front
Immunol, 2019, 10: 1157.